|Table of Contents|

To study the relationship between urine NTX and serum OSC,OPG and NTX in patients with bone metastasis of breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 04
Page:
534-537
Research Field:
Publishing date:

Info

Title:
To study the relationship between urine NTX and serum OSC,OPG and NTX in patients with bone metastasis of breast cancer
Author(s):
Zou Yanpeng; Sun Yu; Qian Pengfei; Li Guanhong; Zhang Shuping
Breast Center,Third People's Hospital of Huizhou City,Guangdong Huizhou 516001,China.
Keywords:
breast cancer; bone metastasis; osteocalcin（OSC); osteoprotegerin（OPG); type I collagen pyridinoline cross-linked N-telopeptides（NTX)
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2018.04.013
Abstract:
Objective:To investigate the relationship between the serum osteocalcin（OSC),osteoprotegerin（OPG),serum and urine type I collagen pyridinoline cross-linked N-telopeptides（NTX) in patients with bone metastasis of breast cancer.Methods:40 cases of breast cancer patients with bone metastasis was experimental group and 40 healthy women was control group,the serum OSC,OPG,NTX,and NTX in urine between the experimental group before treatment and control group was compared.The correlation of serum OSC and serum NTX,serum OPG and serum NTX,serum and urine NTX was evaluated.Results:The serum OSC,OPG and NTX in the experimental group were higher than the control group.The OSC level was statistically significant difference between the two groups（P＜0.001).The OPG level was statistically significant difference between the two groups（P＜0.003).The NTX level was statistically significant difference between the two groups（P＜0.001).The correlation results showed that the serum level of NTX increased had intimate correlation to the serum OSC and OPG level,the correlation coefficient between serum NXT and OSC was 0.768(P＜0.001),the correlation coefficient between serum NXT and OPG was 0.685(P＜0.001),the correlation coefficient between serum and urine NTX was 0.638(P＜0.005),with statistical significance.Conclusion:The serum OSC,OPG,NTX and urine NTX in the breast cancer patients with bone metastasis has a certain correlation,has certain clinical significance.

References:

[1]Barnadas A.Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates:Results from a 2-year multicentre observational study（ZOMAR study)［J］.Bone,2014,68:32-40.
[2] Jung K,Lein M.Bone turnover markers in serum and urine as diagnostic,prognostic and monitoring biomarkers of bone metastasis［J］.Biochim Biophys Acta,2014,18(46):425-438.
[3] Valastyan S,Weinberg RA.Tumor metastasis:Molecular insights and evolving paradigms［J］．Cell，2011,147（2）：275-292.
[4] Eazilaty H,Mehdipour P．Genetics of breast cancer bone metastasis：A sequential multistep pattern［J］．Clin Exp Metastasis,2014,31(5):595-612．
[5] Yu Yang,Zhou Liping.Research progress on molecular mechanisms of breast cancer bone metastasis［J］.Modern Oncology,2014,22(3):693-696.［于洋，周立平.乳腺癌骨转移分子机制的研究进展［J］.现代肿瘤医学,2014,22(3):693-696.］
[6] Chinese Anti-Cancer Association,Committee of Breast Cancer Society.Guidelines for the diagnosis and treatment of breast cancer in Chinese Cancer Society（2015 version）［J］.China Oncology,2015,25(09):692-754.［中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015版)［J］.中国癌症杂志,2015,25(09):692-754.］
[7] Oh D,Huh SJ.Insufficiency fracture after radiation therapy［J］.Radiat Oncol J,2014,32:213-220.
[8] Ming-Xuan Feng,Jian-Xin Hong.Dihydroartemisinin prevents breast cancer-induced osteolysis via inhibiting both breast caner cells and osteoclasts［J］.Scientific Reports,2016,12:1-14.
[9] Aleman JO,Farooki A,Girotra M.Effects of tyrosine kinase inhibition on bone metabolism:Untargeted consequences of targeted therapies［J］.Endocr Relat Cancer,2014,21:R247-R259.
[10] Kamby C,Egsmose C,Soletormos G,et al.The diagnostic and prognostic value of serum bone GLA protein（osteocalcin) in patients with recurrent breast cancer［J］.Scand J Clin Lab Invest,2013,53:439-446.
[11] Henriksen K,Karsdal MA,Martin TJ.Osteoclast-derived coupling factors in bone remodeling［J］.Calcif Tissue Int,2014,94:88-97.
[12]Suva LJ,Makhoul I.Bone:Will breast cancer chemoprevention stand on ｀solid bone'［J］?Nat Rev Endocrinol,2015,11:138-139.
[13] Ottewell PD.Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone［J］.Endocr Relat Cancer,2014,21:769-781.
[14] Tamiya M,Suzuki H,Kobayashi M,et al.Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer［J］.Med Oncol,2015,29:215-218.
[15] Wang Lei,Sun Junying.Clinical significance of serum NTX and ICTP in bone metastasis of breast cancer［J］.Shaanxi Medical Journal,2014,43(02):208-211.［王磊,孙俊英.血清NTX和ICTP检测在乳腺癌骨转移中的临床意义［J］.陕西医学杂志,2014,43(02):208-211.］
[16] Kamby Eswaraka J.Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer［J］.BMC Cancer,2014,14:742-749.
[17] Salem AM,Zohny SF,Abd El-Wahab MM,et al.Predictive value of osteocalcin and beta-cross laps in metastatic breast cancer［J］.Clin Biochem,2016,40:1201-1208.
[18] Demers LM,Costa L,Chinchilli VM,et al.Biochemical markers of bone turnover in patients with metastatic bone disease［J］.Clin Chem,2015,41:1489-1494.
[19] Kaloostian PE,Yurter A,Zadnik PL,et al.Current paradigms for metastatic spinal disease:An evidence-based review［J］.Ann Surg Oncol,2014,21:248-262.
[20] Roodman GD.Genes associate with abnormal bone cell activity in bone metastasis［J］.Cancer Metastasis Rev,2014,10:1055-1112.

Memo

Memo:
广东省惠州市科技计划项目（编号：2014Y153）
Last Update: 2017-12-29